A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This first-in-human dose-escalation study is to characterize the safety, tolerability,
pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in
patients with advanced solid tumors.